Advanced search
1 file | 843.61 KB

Optimising experimental research in respiratory diseases : an ERS statement

Author
Organization
Abstract
Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective. The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research. The task force statement addresses general issues of experimental research (ethics, species, sex, age, ex vivo and in vitro models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension. The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.
Keywords
IDIOPATHIC PULMONARY-FIBROSIS, ACUTE LUNG INJURY, COMMUNITY-ACQUIRED PNEUMONIA, CIGARETTE-SMOKE EXPOSURE, INBRED MOUSE STRAINS, ALLERGIC AIRWAY INFLAMMATION, HIGHLAND WHITE TERRIERS, ANIMAL-MODELS, DISTRESS-SYNDROME, ARTERIAL-HYPERTENSION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 843.61 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bonniaud, Philippe, Aurelie Fabre, Nelly Frossard, Christophe Guignabert, Mark Inman, Wolfgang M Kuebler, Tania Maes, et al. 2018. “Optimising Experimental Research in Respiratory Diseases : an ERS Statement.” European Respiratory Journal 51 (5).
APA
Bonniaud, P., Fabre, A., Frossard, N., Guignabert, C., Inman, M., Kuebler, W. M., Maes, T., et al. (2018). Optimising experimental research in respiratory diseases : an ERS statement. EUROPEAN RESPIRATORY JOURNAL, 51(5).
Vancouver
1.
Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, et al. Optimising experimental research in respiratory diseases : an ERS statement. EUROPEAN RESPIRATORY JOURNAL. 2018;51(5).
MLA
Bonniaud, Philippe, Aurelie Fabre, Nelly Frossard, et al. “Optimising Experimental Research in Respiratory Diseases : an ERS Statement.” EUROPEAN RESPIRATORY JOURNAL 51.5 (2018): n. pag. Print.
@article{8574539,
  abstract     = {Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective. 
The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research. 
The task force statement addresses general issues of experimental research (ethics, species, sex, age, ex vivo and in vitro models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension. 
The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.},
  articleno    = {1702133},
  author       = {Bonniaud, Philippe and Fabre, Aurelie and Frossard, Nelly and Guignabert, Christophe and Inman, Mark and Kuebler, Wolfgang M and Maes, Tania and Shi, Wei and Stampfli, Martin and Uhlig, Stefan and White, Eric and Witzenrath, Martin and Bellaye, Pierre-Simon and Crestani, Bruno and Eickelberg, Oliver and Fehrenbach, Heinz and Guenther, Andreas and Jenkins, Gisli and Joos, Guy and Magnan, Antoine and Maitre, Bernard and Maus, Ulrich A and Reinhold, Petra and Vernooy, Juanita HJ and Richeldi, Luca and Kolb, Martin},
  issn         = {0903-1936},
  journal      = {EUROPEAN RESPIRATORY JOURNAL},
  language     = {eng},
  number       = {5},
  pages        = {34},
  title        = {Optimising experimental research in respiratory diseases : an ERS statement},
  url          = {http://dx.doi.org/10.1183/13993003.02133-2017},
  volume       = {51},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: